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Background: Proopiomelanocortin (POMC)-derived beta-endorphin1-31 from immune cells can inhibit inflammatory
pain. Here we investigated cytokine signaling pathways regulating POMC gene expression and beta-endorphin
production in lymphocytes to augment such analgesic effects.
Results: Interleukin-4 dose-dependently elevated POMC mRNA expression in naïve lymph node-derived cells
in vitro, as determined by real-time PCR. This effect was neutralized by janus kinase (JAK) inhibitors. Transfection of
Signal Transducer and Activator of Transcription (STAT) 1/3 but not of STAT6 decoy oligonucleotides abolished
interleukin-4 induced POMC gene expression. STAT3 was phosphorylated in in vitro interleukin-4 stimulated
lymphocytes and in lymph nodes draining inflamed paws in vivo. Cellular beta-endorphin increased after combined
stimulation with interleukin-4 and concanavalin A. Consistently, in vivo reduction of inflammatory pain by passively
transferred T cells improved significantly when donor cells were pretreated with interleukin-4 plus concanavalin A.
This effect was blocked by naloxone-methiodide.
Conclusion: Interleukin-4 can amplify endogenous opioid peptide expression mediated by JAK-STAT1/3 activation
in mitogen-activated lymphocytes. Transfer of these cells leads to inhibition of inflammatory pain via activation of
peripheral opioid receptors.
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Inflammatory pain is often refractory to conventional
treatments. In addition, currently available opioid analge-
sics have deleterious side effects such as apnoea or ad-
diction, which have recently lead to an epidemic of
overdoses, death and abuse [1]. However, the activation
of opioid receptors on peripheral sensory neurons can
inhibit pain without central or systemic adverse effects.
This can be achieved by exogenous opioids or by en-
dogenous opioid peptides derived from immune cells
[2]. These findings are of clinical relevance since human
pain is exacerbated by interrupting the interaction be-
tween endogenous opioids and their peripheral recep-* Correspondence: melanie.busch@charite.de
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distribution, and reproduction in any mediumtors [3], and is diminished by stimulating opioid
secretion [4]. Advantages of targeting endogenous opioids
include reduced tolerance, receptor down regulation,
desensitization, off-site or paradoxical excitatory effects
due to unphysiologically high exogenous agonist concen-
trations at the receptor [5].
Beta-endorphin1-31 is the most prominent opioid pep-
tide eliciting analgesia in peripheral inflamed tissue [2].
In this environment immune cells can locally secrete
opioid peptides upon stimulation by stress, corticotropin
releasing factor (CRF), catecholamines or chemokines
[3,6,7], resulting in the activation of opioid receptors on
peripheral terminals of sensory neurons and subsequent
analgesic effects [8]. Consistently, stress- and CRF-
induced analgesia is reduced in immunosuppressed rats
and reconstitution of functional lymphocytes has been
shown to reverse this effect [9-11].
In contrast to investigations on the release of opioid
peptides from immune cells, the regulation of opioided Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Expression of cytokines in rat lymph node lysates
draining normal (untreated) and inflamed (2 h
CFA-treated) paws
Cytokine Untreated Inflamed
CINC-2 25.33 ± 7.371 29.67 ± 6.0286
CINC-3 13.33 ± 1.155 19.33 ± 6.028
NGFβ 45.67 ± 6.658 51.76 ± 4.509
CNTF 16.67 ± 3.786 18.33 ± 3.055
Fractalkine 26.67 ± 14.01 28.67 ± 0.577
GM-CSF 15.33 ± 9.074 21.00 ± 2.646
IFN-γ 20.33 ± 5.508 23.67 ± 0.577
IL-10 9.00 ± 8.899 15.00 ± 4.583
IL-1α 12.00 ± 8.718 18.67 ± 0.577
IL-1β 12.00 ± 3.000 19.33 ± 2.309*
IL-4 10.50 ± 0.707 14.67 ± 1.155*
IL-6 9.00 ± 4.359 17.00 ± 8.888
Leptin 16.33 ± 11.240 25.00 ± 0.000
LIX 14.67 ± 11.370 24.00 ± 3.464
MCP-1 25.67 ± 6.807 60.00 ± 35.930
MIP-3alpha 13.67 ± 6.807 22.33 ± 10.500
TIMP-1 32.33 ± 11.930 49.67 ± 9.018
TNF-alpha 17.00 ± 1.732 24.67 ± 13.500
VEGF 30.00 ± 5.196 33.00 ± 10.390
*, unpaired t test with Welch’s correction (P < 0.05).
Data are expressed as percentages of IgG expression in mean ± SD,
n = 3 animals per group.
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been studied in detail so far. Proopiomelanocortin
(POMC) is the precursor of beta-endorphin and POMC-
related peptides are produced in the pituitary, hypotha-
lamus, immune cells and other tissues [12-14]. The
POMC gene comprises three exons that are transcribed
into full-length POMC mRNA. Translation of exons 2
and 3 gives rise to a pre-propeptide. In neuroendocrine
cells, the formation of the active peptides is accom-
plished by entering the regulated secretory pathway and
involves extensive proteolytic cleavage [15]. Current
knowledge about regulatory pathways of beta-endorphin
production in lymphocytes is sparse, predominantly be-
cause full-length POMC mRNA is difficult to detect in
leukocytes [10,16-20]. Using a refined quantitative
methodology, we have demonstrated signal sequence-
encoding POMC mRNA (exons 2–3) and beta-
endorphin in lymph nodes draining inflamed tissue [21].
Others have shown that lymphocytic full-length POMC
mRNA can be induced by concanavalin A (ConA), CRF,
cytokines or phorbolester in vitro but did not delineate
the relevant signaling pathways [22,23]. In pituitary cells,
the transcription factors Tpit and Pitx1 [24,25], Nur77,
and the janus kinase/signal transducer and activator of
transcription (JAK/STAT) are involved in cytokine-
induced POMC gene expression [26,27]. The latter path-
way is also important in the hypothalamic transcription
of the POMC gene induced by leptin [28].
Here we set out to examine cytokines and signaling
molecules involved in POMC gene expression in lym-
phocytes and to test the functional relevance of POMC
stimulation for the inhibition of inflammatory pain
in vivo. Based on the cytokine expression profile in
lymph nodes draining normal and inflamed tissue,
in vitro assays were established to test candidate cyto-
kines individually with respect to their potency to elevate
POMC mRNA levels in naïve node cells. To enhance
cellular activation by mimicking cell-cell contact, lym-
phocytes were exposed to the mitogen ConA [29]. We
hypothesized that peripheral opioid analgesia can be
amplified by transfer of cells primed ex vivo to express
elevated POMC and beta-endorphin.
Results
Exon 2–3 spanning POMC mRNA in lymphocytes is
upregulated by IL-4
To identify potential regulators of POMC gene expres-
sion, we compared the expression profile of inflamma-
tory cytokines in lymph nodes draining normal vs.
inflamed paws 2 h following intraplantar (i.pl.) injection
of Complete Freund’s Adjuvant (CFA). Among nineteen
cytokines analyzed, only IL-1β and IL-4 were signifi-
cantly up-regulated in comparison to lymph node lysates
from healthy animals (Table 1). Stimulation of lymphnode-derived naïve lymphocytes with 5 ng/ml interleu-
kin (IL)-1β for 2 h in vitro did not significantly elevate
POMC exon 2–3 mRNA transcript levels over unstimu-
lated controls (Figure 1A). Dose-dependent increases of
these mRNA transcripts were observed after incubation
with IL-4; a significant elevation over control levels was
obtained with 10 ng IL-4/ml (Figure 1B). No differences
were detectable between untreated and IL-2-, MIP-3α-,
MCP-1- (data not shown), or ConA-treated cells
(Figure 1C).IL-4-induced POMC exon 2–3 mRNA expression in
lymphocytes is mediated via JAK and STAT1/3 signaling
The pan-JAK inhibitor pyridon 6 reduced the IL-4-
induced elevation of POMC mRNA. This inhibition was
significant at concentrations of 0.3 and 0.6 μM
(Figure 1D). The JAK1/3 inhibitor A771726 (125 μM),
but not the STAT6 inhibitor cyclic pifithrin-alpha, sig-
nificantly decreased the IL-4-induced elevation of
POMC mRNA (Figure 1E, F). IL-4-induced POMC
mRNA levels were significantly attenuated by STAT1/3
but not by STAT5 or −6 decoy oligonucleotides
(Figure 1G, H, I). After exposure of naïve cells to IL-4,
cell lysates were analyzed using Western Blotting.
Figure 1 IL-4 induces POMC exon–3 mRNA expression in
lymphocytes via JAK/STAT signaling. Lymphocytes were
incubated for 2 h in the presence of A) IL-1β (n = 5), B) IL-4 (n = 6),
and C) ConA (n = 3) at the indicated concentrations. D-F) Node cells
were preincubated with indicated doses of pyridon 6 (n = 5), A77
1726 (n = 4) or cyclic pifithrin-alpha (n = 5) prior to IL-4 addition. H-I)
Lymphocytes were transfected 24 h prior to the addition of IL-4 with
STAT6 (n = 5), STAT5 (n = 6), and STAT1/3 (n = 6) decoy
oligonucleotides at the indicated concentrations. In A-C POMC mRNA
ratios are given in relation to unstimulated controls; in D-I POMC mRNA
ratios are given in relation to inhibitor-free, IL-4 stimulated controls. Data
represent means ± SEM. Statistical analysis was performed on raw data
of A+C using the Wilcoxon signed rank test; raw data of B and D-I were
analyzed using the Friedmann and Dunn’s test *P < 0.05; **P < 0.01.
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phosphorylations, which were abolished by pyridon 6
pretreatment (see Figures. 2B and C). Significant differ-
ences were observed between treatment groups for STAT3
and STAT5 phosphorylation (Friedman test, p < 0.05). Posthoc comparison using Dunn’s test revealed significant dif-
ferences for Tyrosine-phosphorylation of STAT3 between
IL-4 and IL-4 plus 0.16 and 0.66 μM pyridon 6 treated
cells. For STAT5 phosphorylation the post hoc comparison
remained insignificant. Phosphorylation of STAT3 at
Serine 727 was not observed (Figure 2A), while slight
STAT3 acetylation at Lysine 685 was observed in unstimu-
lated, IL-4-treated, and pyridon 6 pretreated cells and
appeared to be unaffected by the cell treatments
(Figure 2C, Friedman test, p > 0.05). Akt phosphorylation
at Serine 473 was present after IL-4-stimulation and ab-
sent in cells pretreated with pyridon 6 (Figure 2B, Fried-
man test, p < 0.05). However, post hoc comparison for Akt
phosphorylation remained insignificant. Phosphorylation
of extracellular-signal regulated kinase (ERK) 2 (p42) and
of mitogen-activated protein kinase p38 remained largely
unaffected by IL-4-stimulation (Figure 3) but phosphoryl-
ation of both kinases tended to increase in IL-4 plus pyri-
don 6 treated cells. Significant differences between
treatment groups were observed for p42-phosphorylation
(Friedman test, p < 0.05). Post hoc comparison using
Dunn’s test revealed significant differences for p42-
phosphorylation between untreated controls and IL-4 plus
0.66 μM pyridon 6 treated cells.
IL-4 treatment elevates beta-endorphin content and
release from mitogen-activated lymphocytes
Cellular amounts of immunoreactive beta-endorphin did
not change in naïve lymphocytes stimulated with IL-4 for
24 h (Figure 4A). To mimick cell activation, naïve lympho-
cytes were incubated for 24 h with ConA, which had no
effect on the cellular levels of immunoreactive beta-
endorphin (Figure 4A). However, the combined stimula-
tion with ConA and IL-4 significantly increased contents
of immunoreactive beta-endorphin (Figure 4A). Vesicular
release was induced by ionomycin-treatment. Extracellular
levels of immunoreactive beta-endorphin were signifi-
cantly higher than controls when cells were pre-
stimulated with combined but not separate ConA and
IL-4 (Figure 4B). Ionomycin-induced release of immunor-
eactive beta-endorphin from ConA/IL-4 stimulated cells
was not significantly influenced by up to 1 μM pyridon 6
pretreatment (Figure 4B).
Transfer of mitogen-activated lymphocytes pretreated
with IL-4 restores opioid antinociception in immune
cell-depleted rats
Four days after i.pl. injection of Complete Freund’s Ad-
juvant (CFA), paw pressure thresholds (PPT) in inflamed
(ipsilateral) paws were significantly lower than in nonin-
flamed (contralateral) paws of rats immunosuppressed
by cyclophosphamide (CTX, Figure 5). Intraplantar
transfer of unstimulated or stimulated cells did not
change the reduced PPT (hyperalgesia) in inflamed paws
Figure 2 IL-4-activated JAK signaling results in the phosphorylation of STATs and Akt. Lymphocytes were preincubated for 30 min prior to
the addition of IL-4 with/without pyridon 6. After 2 h IL-4 stimulation, activation of JAK downstream signaling molecules (others than STAT6) was
investigated in cell lysates using Western Blotting followed by densitometry. Representative immunoblots are shown; the same blot was probed
sequentially with different antibodies. Densitometry results are given as mean % expression of loading control ± SEM in the bar graphs; statistical
analysis was performed using the Friedman and Dunn’s test; *P < 0.05. A) Phosphorylation of STAT1 (Tyrosine 701, 84/91 kDa) and STAT3
(Tyrosine 705, 79/86 kD and Serine 727, 86 kDa) and inhibition by pyridon 6; loading was controlled by staining for non-phosphorylated STAT3
(79/86 kDa). The bar graphs show the mean expression of phosphorylated STAT1 (n = 3 independent experiments), Tyrosine-phosphorylated
STAT3 (n = 6 independent experiments, and Serine-phosphorylated STAT3 (n = 3 independent experiments) in % of STAT3, respectively.
B) Phosphorylation of STAT5 (Tyrosine 694, 90 kDa) and of Akt (Serine 473, 60 kDa) and inhibition by pyridon 6; loading was controlled by
staining for beta-actin (42 kDa). The bar graphs show the mean expression of phospho-STAT5 (n = 3 independent experiments) and phospho-Akt
(n = 3 independent experiments) in % of beta-actin, respectively. C) Acetylation of STAT3 (Lysine 685, 79/86 kDa) and inhibition by pyridon 6;
loading was controlled by staining for STAT3 (79/86 kDa). The bar graph shows the expression of Acetyl-STAT3 (n = 3 independent experiments)
in % of STAT3. Ac; acetylated; Lys; Lysine; Ser, Serine; Tyr, Tyrosine.
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i.pl. injection of 1.5 ng CRF completely reversed hyper-
algesia in paws injected with ConA/IL-4-stimulated T
cells compared to all other groups, such that PPT were
similar to contralateral noninflamed paws (Figure 5).
CRF-induced increases of ipsilateral PPT values were sig-
nificantly higher in animals receiving 1×105 (63.8 ±
4.4 g) and 5×105 (65.0 ± 7.3 g) ConA/IL-4 treated cells
in comparison to 10×105 cells (53.8 ± 8.0 g) (One-Way
ANOVA and Bonferroni’s Test, P < 0.05). Therefore,
subsequent experiments were performed with the lowest
cell number. Four days after i.pl. CFA, PPT were ana-
lyzed in immunosuppressed (Figure 6A) and in immuno-
competent (Figure 6B) animals pretreated with s.c. NLX
prior to CRF injection. PPT in immunosuppressed ver-
sus immunocompetent rats were slightly but signifi-
cantly lower in both contralateral (64.4 ± 1.0 g versus
68.1 ± 1.0 g, respectively; unpaired t-test, P < 0.05, 8 rats
per group) and in inflamed paws (29.4 ± 1.2 g versus36.04 ± 0.8 g, respectively, unpaired t-test, P < 0.05, 8 rats
per group). Baseline PPT in inflamed paws were not influ-
enced by NLX. In recipients of ConA/IL-4-stimulated
cells, NLX completely reversed CRF-induced increases of
PPT (Figure 6A). In immunocompetent rats, CRF-induced
PPT elevations in inflamed paws were significantly higher
than in contralateral paws. This effect was abolished by
NLX (Figure 6B).
STAT3 and Akt are phosphorylated in lymph nodes
draining inflamed tissue in vivo
At 1 and 2 h after induction of CFA-inflammation in vivo,
phosphorylated STAT6 was undetectable in cells isolated
from ipsi- and contralateral popliteal lymph nodes
(Figure 7A). Tyrosine-phosphorylation of STAT3 was
observed in cells from ipsi- and contralateral nodes
(Figure 7B). Densitometry showed that at both 1 and 2 h
post CFA-injection, this phosphorylation was significantly
stronger in the ispilateral than in the contralateral node
Figure 4 Cellular levels of beta-endorphin immunoreactivity
increase in ConA-activated and IL-4-stimulated lymphocytes.
A) 24 h after cell stimulation with/without IL-4 (10 ng/ml) and ConA
(1 μg/ml), beta-endorphin immunoreactivity was determined in cell
lysates. Data represent the beta-endorphin immunoreactivity in
pg/1.0E+06 cells of n = 6 independent experiments; median is
indicated by the horizontal line. B) Ionomycin-induced release of
immunoreactive beta-endorphin was determined using EIA in the
supernatant of cells stimulated for 24 h with/without IL-4 (10 ng/ml),
ConA (1 μg/ml), and pretreated with pyridon 6 at the indicated
doses. Data represent the beta-endorphin immunoreactivities in
pg/1.0E+06 cells of n = 8 independent experiments; median is
indicated by the horizontal line. All data were analyzed using
Friedmann and Dunn’s Test in comparison to unstimulated controls
(*P < 0.05).
Figure 3 IL-4 and pyridon 6 do not interfere with MAP kinase
pathways. Lymphocytes were preincubated for 30 min with/
without pyridon 6 and stimulated for 2 h with IL-4. Cell lysates were
subjected to Western Blotting followed by densitometry.
Representative immunoblots show p42 and p38 phosphorylation;
loading was controlled by staining for non-phosphorylated p44/42
(42/44 kDa) and non-phosphorylated p38 (38 kDa), respectively.
Densitometry results are given as mean % expression of loading
control ± SEM in the bar graphs; statistical analysis was performed
using the Friedman and Dunn’s test; *P < 0.05. The number of
independently performed experiments was n = 4 for p42 and n = 3
for p38 phosphorylation.
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phosphorylation of STAT3 and Tyrosine-phosphorylation
of STAT1 were not detectable in cells from ipsi- or
contralateral nodes (Figure 7B). Despite background,
Threonine-phosphorylation of Akt was detectable in cells
from the ipsi- and contralateral nodes, but no reliable
densitometric analysis could be performed.Discussion
In the present study we found that: i) signal sequence-
encoding POMC mRNA expression can be induced in
naïve lymph node-derived cells by IL-4 stimulation
in vitro, ii) POMC exon 2–3 mRNA up regulation by IL-
4 is at least partially mediated via the JAK-STAT path-
way involving Tyrosine-phosphorylated STATs 1 and −3,
but not STAT5, STAT6, ERK 2 or p38 MAPK, iii) IL-4
induces beta-endorphin production in mitogen-activated
lymphocytes, and iv) in vivo transfer of IL-4-stimulated,
mitogen-activated T lymphocytes restores CRF-induced,
opioid-mediated analgesia in immune cell-depleted
animals.
Figure 5 Transfer of cytokine-stimulated T cells restores
CRF-induced antinociception in immunosuppressed rats with
hindpaw inflammation. Cyclophosphamide (CTX)-pretreated rats
with CFA-induced hindpaw inflammation were injected i.pl. with
untreated, ConA-, IL-4- or ConA/IL-4-pretreated T cells. PPT were
determined in the ipsilateral and contralateral paw at baseline, after
T cell transfer, and after i.pl. CRF injection. Controls received i.pl.
vehicle. Data represent means ± SD (n = 7–8 animals per group).
PPT values were analyzed for effects of the injection (baseline, T cell
transfer, and CRF-injection) and between paws (ipsi versus
contralateral) using Two-Way RM ANOVA and Bonferroni’s Test. §,
Ipsilateral PPT are significantly lower than contralateral values at
baseline (P < 0.001); §§, Ipsilateral PPT are significantly lower than
contralateral values after T cell-injection (P < 0.001); #, Ipsilateral PPT
are significantly lower than contralateral values after CRF-injection (P
< 0.001). Effects of treatment (vehicle versus unstimulated, ConA-, IL-
4-, and ConA/IL-4-stimulated T cells) and injection (baseline, T cell
transfer, and CRF-injection) on ipsilateral PPT values were analyzed
using Two-Way RM ANOVA and Bonferroni’s Test. ***, Ipsilateral PPT
are significantly elevated in recipients of ConA/IL-4-stimulated T cells
after CRF-injection (P < 0.001).
Figure 6 CRF-induced antinociception in recipients of activated,
ConA/IL-4-stimulated T cells is opioid mediated. A) NLX
reversibility of CRF-induced antinociception in CTX-treated recipients of
T cells stimulated with ConA/IL-4. PPT were determined at baseline
and after i.pl. injections of T cells and CRF. Controls received s.c. NaCl.
B) CRF-induced antinociception and NLX-reversibility in non-
immunosuppressed rats. PPT were determined at baseline and after
CRF injection. Data represent means ± SD (n = 7–8 animals per group).
Effects of the injection (baseline versus CRF) and of the treatment
(saline versus NLX) on ipsilateral PPT were analyzed using Two-Way RM
ANOVA and Bonferroni’s Test. §§§, CRF injection significantly elevated
PPT in NaCl-treated animals (P < 0.001); ***, CRF-induced elevation of
PPT is significantly reduced by NLX (P < 0.001).
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nal sequence-encoding POMC mRNA in the draining
lymph node increase as early as 2 h post induction of
paw inflammation in rats [21]. In neuroendocrine cells
the translational product of such mRNA transcripts - in
contrast to that of truncated POMC transcripts lacking
exon 2 - can enter the secretory pathway [30], which is a
prerequisite for the formation and secretion of biologically
active POMC-derived peptides including beta-endorphin.
However, the regulation of POMC gene expression and
processing in immune cells has not been studied in detail
so far. We now identified elements that are involved in
the transcriptional regulation of POMC expression in lym-
phocytes. ConA did not enhance POMC exon 2–3 mRNA
levels within the relative short time frame of 2 h. Others
found ConA-induced POMC mRNA elevation in spleno-
cytes incubated for 21 h with this mitogen [22]. In our
experiments IL-1β treatment only slightly elevated POMC
exon 2–3 mRNA levels after 2 h. This resembles previous
findings in human dermal endothelial and in corticotroph
AtT-20 cells [31,32]. Similarly, IL-2 did not elevate thePOMC mRNA in our study or in AtT-20 cells [32,33] but
IL-4 induced a considerable increase. So far this cytokine
was not investigated with respect to POMC mRNA ex-
pression in lymphocytes but it was found to stimulate
proenkephalin mRNA in peripheral blood mononuclear
cells [34].
The predominant pathway of IL-4-induced gene tran-
scription in T and B cells involves JAK1/3 and STAT6
activation [35]. This was also found in case of the μ-
opioid receptor [36]. Thus, we hypothesized that the in-
duction of lymphocytic POMC gene expression by IL-4
is mediated via the JAK-STAT6 pathway. Indeed, the IL-
4 effect was fully blocked by the pan JAK inhibitor pyri-
don 6 and by the JAK1/3 inhibitor A771726, but not by
the proposed STAT6 inhibitor cyclic pifithrin-alpha. In
addition, it was not attenuated by STAT6 but partially
by STAT1/3 decoy oligonucleotides. Others demon-
strated that phospho-STAT3 activated the POMC pro-
moter through an indirect mechanism requiring an
SP1-binding site [28], and that STAT3 and the AP-1
protein complex can cooperate in driving transcription
[37]. In pituitary corticotrophs leukemia inhibitory fac-
tor induced POMC gene expression via binding of
phosphorylated STAT1 and −3 homo- and heterodimers
to the promoter [38]. In line with these findings, we
detected considerable STAT1 phosphorylation in IL-4
treated lymphocytes. Also, following IL-4 stimulation
STAT3 was strongly phosphorylated at Tyrosine 705,
Figure 7 Phosphorylation of JAK downstream targets in cells
from lymph nodes draining inflamed and noninflamed paws.
Popliteal lymph nodes (i, ipsilateral; c, contralateral) were dissected
from two animals each at 1 and 2 h post i.pl. CFA injection: Cells were
isolated and cell lysates were analyzed using Western Blotting.
Densitometry results are given as mean % expression of loading
control ± SEM in the bar graphs. A) Tyrosine 641-phosphorylation of
STAT6 (110 kDa) in CFA- and IL-4-stimulated lymphocytes, two out of 6
nodes analyzed per time point are shown. A commercially available
phospho-STAT6 positive control (POS, BioLabs) was run on the same
gel. M = protein marker. B) Tyrosine 705 (79/86 kDa)- and Serine 727
(86 kDa)-phosphorylation of STAT3, non-phosphorylated STAT3
(79 kDa), phosphorylated STAT1 (84/91 kDa), non-phosphorylated
STAT1 (84/91 kDa), Threonine 308-phosphorylated Akt (60 kDa), and
non-phosphorylated Akt (60 kDa). Stainings were performed on 3
nodes per time point; the staining for Tyrosine-phosphorylated STAT3
was performed on 6 nodes per time point. Statistical comparison of
the ipsi- and contralateral side was performed using the Wilcoxon
Matched Pair test; *P < 0.05. Representative immunoblots are shown.
The same blot was probed sequentially with different antibodies. Lanes
shown were run on the same gel, noncontiguous lanes are separated
by thin white lines. Ser, Serine; Thr, Threonine; Tyr, Tyrosine.
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This is in agreement with IL-4-induced, JAK3-mediated
phosphorylation of STAT3 in naïve cytotoxic T cells
[39]. We did not observe STAT3 phosphorylation at
Serine 727. Others demonstrated that DNA binding of
STAT1 or −3 is not affected by Serine-phosphorylation
[40], indicating that Tyrosine-phosphorylation is suffi-
cient for the induction of gene transcription. In line
with this notion, leukemia inhibitory factor-induced
POMC transcription in the pituitary was abrogated by
mutated STAT3 containing Phenylalanine instead of
Tyrosine 705 [41].
IL-4 can also activate the phosphoinositide 3-kinase
kinase/protein kinase B (Akt) pathway [42]. Concor-
dantly, we found Akt phosphorylation. In addition, this
pathway is known to activate Ras-Raf-Mitogen-Activated
Protein kinases (MAPK) including phospho-p44/42
(ERK 1 and 2). We found that ERK 2 was already highly
phosphorylated in unstimulated lymphocytes and was
apparently not changed after treatment with IL-4 or with
pyridon 6. Together, these findings suggest that the
MAPK pathway is not essential for IL-4-induced POMC
gene expression in lymphocytes, which resembles find-
ings in AtT-20 cells [41]. This is also supported by the
lack of STAT3 Serine-phosphorylation after IL-4 treat-
ment, which would be expected via the Ras-Raf-MAPK
pathway activation [43]. In contrast to human neutro-
phils [44], we found that p38 MAPK was phosphorylated
in both naïve and IL-4-stimulated lymph node-derived
cells. Additionally, phosphorylation of p38 was not sig-
nificantly affected by pyridon 6. Thus, we conclude that
p38 is not involved in IL-4-induced POMC gene expres-
sion in lymphocytes.
We then analyzed whether IL-4-treatment increased the
cellular beta-endorphin content and in vivo antinocicep-
tive function. To obtain significant opioid peptide levels
and release in vitro, we had to prime naïve cells with the
mitogen ConA, similar to others [11]. This suggests that
POMC gene expression and precursor processing are in-
dependently regulated in lymphocytes. Inflammatory cells
express POMC processing enzymes [45,46], but their
functional role in the regulation of processing pathways
and beta-endorphin production have not been elucidated.
To investigate antinociceptive effects of T cell-derived
opioids, we used immune cell-depleted rats and stimula-
tion with CRF, which has been shown to release opioid
peptides in vitro and in vivo [9,16]. In recipients of ConA/
IL-4-stimulated T cells this resulted in strong antinocicep-
tion in inflamed paws. In contrast to findings after intra-
venous cell transfer [11], this effect did not increase
with rising cell numbers. Since we administered the
cells directly to the site of inflammation, lower num-
bers may be required. The same CRF dose injected
into immunocompetent animals induced a stronger
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cell recipients, indicating that CRF was not the limit-
ing factor. The antinociceptive effect was blocked by
naloxone-methiodide, consistent with the notion that
it was mediated by opioid receptors on peripheral
terminals of sensory neurons [8]. Together with our
in vitro data, these findings indicate that the produc-
tion of biologically active beta-endorphin is enhanced
by treatment of mitogen-activated lymphocytes with
IL-4, and that this strategy can be used to amplify
opioid inhibition of inflammatory pain in vivo. Thus,
we have discovered a new mechanism, adding to pre-
vious reports showing antinociceptive effects of IL-4
via the inhibition of pro-inflammatory cytokines
[47,48]. In those studies, pain thresholds were deter-
mined 30 min after IL-4 injection and the effects
were not reversed by naloxone. In our experiments,
the opioid-dependent antinociceptive effects produced
by passively transferred T lymphocytes pretreated for
24 h with IL-4 plus ConA were detected only after
injection of CRF. This further supports the concept
that IL-4 induces the production rather than the re-
lease of opioid peptides in activated lymphocytes.
Finally, to obtain information on the JAK/STAT signal-
ing molecules at early stages of inflammation in vivo, we
analyzed lymph nodes dissected after induction of unila-
teral paw inflammation by CFA. Phosphorylated STAT6
was undetectable in all tissues. This finding indicates that
IL-4 was not released after CFA-inoculation, at least not
at substantial concentrations. However, STAT3 Tyrosine-
phosphorylation was increased in cells from ipsilateral
lymph nodes. Taken together, these findings indicate that
the in vivo elevation of POMC mRNA may be due to
STAT3 phosphorylation and this effect can be mimicked
in vitro by stimulating naïve lymphocytes with IL-4.
In summary, our present and previous data show that
beta-endorphin-containing lymphocytes infiltrating
inflamed tissue can produce opioid mediated antinoci-
ception [11,49,50]. This is also supported by the
present finding of increased nociception in immuno-
suppressed as compared to immunocompetent animals
with hind paw inflammation. Furthermore, we have
now demonstrated that POMC and beta-endorphin
production as well as pain inhibition can be signifi-
cantly augmented by IL-4-induced activation of the
JAK/STAT pathway. This should spawn innovative
approaches to pain therapy, for example antigenic
stimulation (similar to vaccination), clonal expansion,
or genetic manipulation of such cells [51]. Pain relief
via enhancement of endogenous opioid production in
immune cells may overcome limitations of conven-
tional analgesics such as addiction, paradoxical hyper-
algesia, cognitive impairment, nausea and constipation
induced by opioid drugs, or gastrointestinal ulcers,bleeding, and cardiovascular complications produced
by cyclooxygenase inhibitors.
Conclusion
The expression of POMC and beta-endorphin in lym-
phocytes is apparently linked to anti-inflammatory cyto-
kines and JAK-STAT1/3 activation. Interleukin-4
effectively stimulated POMC transcription in naïve cells.
Evidently, precursor processing is regulated independ-
ently from gene transcription by so far unidentified fac-
tors during cell activation. Our data provide a novel
in vitro model to study the molecular mechanisms
involved in opioid peptide synthesis in such cells and
outline novel approaches to pain treatment by promo-
ting production of immune cell derived opioid peptides.
Materials and methods
Experimental animals and induction of inflammation
Experiments were approved by the animal care commit-
tee of the State of Berlin and strictly followed the guide-
lines of the International Association for the Study of
Pain [52]. Male Wistar rats (225–300 g, Charles River
Breeding Laboratories) received an i.pl. injection of
0.15 ml Complete Freunds’ Adjuvant (CFA, Calbiochem,
La Jolla, CA, USA) into the right hind paw under brief
isoflurane (Rhodia Organic Fine Ldt., Bristol, UK)
anesthesia. The inflammation remained confined to that
paw throughout the observation period.
Cytokine array
Popliteal lymph nodes draining normal and inflamed hind
paws (2 h post CFA) were dissected, homogenized, and
lyzed. Expression of cytokines was analyzed using Ray-
BioTM Rat Cytokine Antibody Array 1.1 kits (RayBiotech,
Inc., Norcross, GA, USA) following the manufacturer’s
instructions. Array-membranes carrying antibodies for the
detection of nineteen cytokines and anti-rat IgG (loading
control) were incubated with the lymph node lysates
(500 μg protein/membrane) for 2 h. After washing, the
membranes were incubated for 2 h with a mixture of
biotin-conjugated antibodies, followed by peroxidase-
conjugated streptavidin. Immunoreactive dots were subse-
quently visualized using an enhanced chemiluminescence
(ECL) system, and membranes were exposed to autoradio-
graph hyperfilms for 10 to 30 seconds.
Preparation of lymphocytes
Healthy rats were sacrificed by isoflurane overdose. Pop-
liteal, axillary, and inguinal lymph nodes were dissected
and pooled. Our previous flow cytometry analyses had
shown that about 95% of cells residing in naïve nodes
express the hematopoietic cell marker CD45, 70-80% are
CD3+ T lymphocytes, and 20-25% are IgG kappa light
chain+ B lymphocytes [21]. Lymphocytes were
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cell strainers and were cultured in RPMI-1640 medium
containing 1% penicillin/streptomycin under standard
culturing conditions (37°C and 5% CO2) unless other-
wise stated.
Cytokine stimulation and inhibitor treatment of
lymphocytes
Naïve lymphocytes were stimulated for 2 or 24 h with
0.1 – 10 ng/ml of rat recombinant cytokines and chemo-
kines (IL-1β, -2, -4, -10, MIP-3α, or MCP-1, all from
R&D Systems, Wiesbaden, Germany), and with the
mitogen ConA (1 μg/ml, Sigma-Aldrich). After stimula-
tion, cells were collected on ice, centrifuged, and pellets
were stored at −80°C.
Cells were pretreated with permeable small molecule
inhibitors (Calbiochem, EMD Chemicals Inc., an Affili-
ate of Merck KgaA, Darmstadt, Germany) prior to the
addition of the stimulants. Pyridon 6, a pan-JAK inhibi-
tor, was applied at concentrations of 0.16, 0.3, 0.6 and
1 μM for 30 min [53]. To inhibit JAKs 1 and 3, the ac-
tive metabolite of leflunomide, A771726, was added for
120 min (75 and 125 μM) [54]. The STAT6 inhibitor
cyclic pifithrin-α was applied for 30 min (0.1, 0.5, 1, 5,
10 and 50 μM) [55].
Cell transfection and decoy oligonucleotide-experiments
Double-stranded decoy oligonucleotides (TIBMOLBIOL,
Berlin, Germany) providing binding motifs for STAT6
(50-gATCCTACTTCATggAAgAAT-30), STAT1/3 (50-
gATCgAgTTTACgAgAACTC-30), or STAT5 (50-gATCg
CATTTCggAgAAgACg-30) were prepared as described
without chemical modifications [56]. Cells were diluted
in antibiotic-free culture medium containing 10% serum
and were plated for transfection on 6-well-plates
(10 cm2 surface area) using the BLOCKiTTM Transfec-
tion Kit (Invitrogen GmbH, Karlsruhe, Germany)
according to the manufacturer’s instructions. The trans-
fection reagent Lipofectamine 2000TM (5 μl/well) was
mixed with 50, 100 or 200 pmol decoy oligonucleotide
solutions to allow complex formation prior to addition
of the mixture to the cells. Cells were then incubated at
37°C and 5% CO2. A non-target, fluorescein-labeled
double-stranded RNA oligomer (BLOCKiTTM fluores-
cent oligo) was used as an indicator of transfection effi-
ciency. Uptake of the BLOCKiT oligo was observed
already at 6 h post transfection and persisted for at least
24 h in the cells, as assessed using a fluorescence micro-
scope. Accordingly, medium was replaced 24 h after
transfection by pure RPMI-1640 medium, then cytokine
was added and cells were incubated for another 2 h at
37°C and 5% CO2. Thereafter, cells were collected on
ice, centrifuged, and pellets were stored at −80°C until
POMC exon 2–3 mRNA was assayed using qRT-PCR.Radioimmunoassay and Enzyme Immuno Assay
Cellular content of beta-endorphin was determined by
measuring immunoreactive beta-endorphin in cell
lysates using a rat radioimmunoassay (RIA) kit according
to the manufacturer’s instructions (Phoenix Peptides
Inc., Burlingame, CA, USA) and as previously described
[21,57]. Briefly, lymphocytes were lyzed by sonication
(15 sec, 1 impulse/sec) at a concentration of approxi-
mately 3 × 106 cells per 100 μl assay buffer and beta-
endorphin immunoreactivity was determined in 100 μl
of the lysates in duplicate.
The release of beta-endorphin was determined in cell
supernatants using a human/rat-fluorescent EIA kit
according to the manufacturer’s instructions (Phoenix
Peptides Inc.) as previosly described [7] Briefly, release
was induced by incubation of approximately 6× 106
cells/120 μl RPMI-1640 medium containing 10 μM iono-
mycin (Sigma-Aldrich). Cells were then incubated for
7 min at 37°C and 600 rpm in a thermal heating block,
chilled on ice, and centrifuged for 10 min at 450 × g and
4°C. Wells of EIA plates were loaded with 50 μl of the
supernatants each; beta-endorphin immunoreactivity
was assessed in duplicate.
Western Blot analysis
Western Blotting was performed as previously described
[46]. Briefly, cells were sonicated and homogenized in
RIPA buffer [50 mM Tris–HCl (pH 8.0); 150 mM NaCl;
1% Nonidet P-40 (v/v); 0.5% Desoxycholat (w/v); 0.1%
SDS (w/v)] in the presence of protease and phosphatase
inhibitors (Complete mini and PhosSTOP tablets, Roche).
Proteins (30–50 μg/sample) were subjected to polyacryl-
amide gel-electrophoresis, the gels were composed of an
upper stacking and a lower resolving part according to the
method of Laemmli [58]. After separation, proteins were
transferred at 350 mA/60 min to Immobilon-P mem-
branes (Millipore Corperation, Billerica, MA, USA). Mem-
branes were blocked in Tris buffered saline containing
2.5% bovine serum albumin and 0.1% Tween-20 for at
least 30 min at room temperature. After blocking, blots
were sequentially probed with the following polyclonal
rabbit antibodies overnight at 4°C: anti-phospho-STAT1
(Tyrosine 701, 84/91 kDa), anti-STAT1 (84/91 kDa), anti-
phospho-STAT3 (Tyrosine 705, 79/86 kDa), anti-
phospho-STAT3 (Serine 727, 86 kDa), anti-acetyl-STAT3
(Lysine 685, 79/86 kDa), anti-STAT3 (79/86 kDa), anti-
phospho-STAT5 (Tyrosine 694, 90 kDa), anti-STAT5
(90 kDa), anti-phospho-STAT6 (Tyrosine 641, 110 kDa),
anti-STAT6 (110 kDa), anti-phospho-Akt (Threonine 308,
60 kDa), anti-phospho-Akt (Serine 473, 60 kDa), anti-Akt
(60 kDa), anti-phospho-p44/42 (recognizes p42 when
phosphorylated at Threonine 183/Tyrosine 185 in the rat,
42 kDa), anti-p44/42 (42/44 kDa), as well as with anti-
phospho-p38 (Threonine 180/Tyrosine 182, 38 kDA) and
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blocking buffer and purchased from Cell Signaling Tech-
nologies (Danvers, Massachusetts, USA). After incubation
with peroxidase-conjugated secondary antibodies (goat
anti-rabbit IgG and rabbit anti-mouse IgG purchased
from Jackson ImmunoResearch Europe Ltd., Suffolk,
UK) diluted 1/5000 in blocking buffer, immunoreactive
bands were visualized using an ECL system. Peroxidase-
conjugated anti-beta-actin (42 kDa) was purchases from
Sigma-Aldrich and diluted 1:50,000 in blocking buffer;
this antibody renders the use of a secondary antibody
before overlay of the blot with ECL solution unneces-
sary. Exposure time of the blots to autoradiograph
hyperfilms was 10 to 120 s. Bound antibodies were
removed by stripping for 15 min at 50°C in 62.5 mM
Tris–HCl containing 100 mM beta-Mercaptoethanol
and 2% SDS. Controls included reprobing upon omis-
sion of primary or secondary antibodies.
PCR primers and quantitative real-time PCR (qRT-PCR)
Primers were designed to amplify POMC and ribosomal
protein L19 mRNA transcripts using OLIGO Primer Ana-
lysis Software Version 5.0 for Windows. Oligodeoxynu-
cleotides were synthesized and purified by TIBMOLBIOL.
Real-time PCR assays were performed using the Fast start
DNA Master SYBR Green I assay (Roche) according to
the instructions of the manufacturer in a LightCycler 1.5
instrument including melting curve analyses. Positive con-
trols contained pituitary cDNA; negative controls con-
tained double-distilled H2O or RT
- cDNA. Amplification
was performed as detailed in Sitte et al. [21], all samples
but positive and negative controls were run in duplicate.
For some measurements, sensitivity for POMC mRNA
amplification was enhanced using a semi-nested real-time
PCR protocol as previously described [21]. The amount of
POMC exon 2–3 transcripts (sense primer: 50-CCCTCCT
GCTTCAGACCTCCA-30, antisense primer: 50-TCTCTT
CCTCCGCACGCCTCT-30) was normalized to the ex-
pression levels of ribosomal protein L19 using exon 2–5
spanning primers (sense primer: 50-AATCGCCAATGC
CAACTCTCG-30, antisense primer: 50-TGCTCCATGA
GAATCCGCTTG-30), treatment effects were evaluated by
applying the delta-delta CP method as detailed below.Immunosuppression of rats and measurement of
nociceptive thresholds
Rats were handled daily for 4 days. They were treated
thrice at intervals of 48 h intraperitoneally (i.p.) with cyclo-
phosphamide (CTX, Baxter Oncology) to induce depletion
of immune cells as previously described [49]; a single i.pl.
CFA injection into the right hind paw was given 72 h after
the first CTX-injection. At 96 h post CFA-inoculation, im-
munosuppressed rats received purified T lymphocytes intoinflamed paws (i.pl.); control animals were injected with
vehicle (PBS). These T cells were obtained from pooled
axilliary and inguinal lymph nodes of healthy donor rats as
detailed above. Cells were treated for 24 h with/without
ConA (1 μg/ml), IL-4 (10 ng/ml), or ConA plus IL-4
ex vivo. Then cell suspensions were depleted of MHC
class II receptor+ and CD45RA+ cells (dendritic cells,
monocytes/macrophages, and B lymphocytes) using mag-
netic cell sorting columns, anti-rat MHC class II receptor
and anti-rat CD45RA beads (Miltenyi Biotec, Bergisch
Gladbach, Germany), similar to Sitte et al. 2007 [21]. This
procedure revealed > 95% pure T cell suspensions that
were reconstituted at 1× 105, 5× 105 and 10× 105 cells per
50 μl PBS for i.pl. injections. In the first set of experiments,
animals received i.pl. CRF (1.5 ng/50 μl) to induce opioid
peptide release 10 min after i.pl. T cell administration. In
the second experiment, naloxone-methiodide (NLX;
10 mg/kg) or vehicle (saline) were injected subcutaneously
(s.c.) 5 min after i.pl. T cell administration. Another 5 min
later the animals received i.pl. CRF (1.5 ng/50 μl). Another
group of immunocompetent rats received s.c. NLX or ve-
hicle, followed by i.pl. CRF.
Mechanical hyperalgesia was tested by measuring paw
pressure thresholds (PPT) (modified Randall–Selitto test;
Ugo Basile) as previously described [59]. Measurements
were performed immediately before (baseline) and 7 min
after T cell transfer, as well as 5 min post CRF injection.
Three consecutive trials, separated by 10 s intervals
each, were conducted and the average was calculated.
The sequence of left and right paws was alternated be-
tween animals to avoid bias. The experimenter was blind
to the treatment.Data processing
POMC and ribosomal protein L19 qRT-PCR data were
analyzed using the LightCycler software 3.5 (Roche).
Levels of transcripts were assessed as crossing points (CP)
when specific amplification exceeded background fluores-
cence using the Second Derivative Maximum analysis
method of the system. Average PCR efficiencies were 1.89
for rpL19 and 1.82 for POMC exon 2–3 transcripts. All
data were subsequently extrapolated using MS Excel 2003.
Differences between treated and untreated cells are shown
as mean POMC exon 2–3 mRNA ratios ± SEM and were
calculated by applying the delta-delta method: Ratio =
(PCR efficiency of POMC)^delta CPPOMC(control-sample)/
(PCR efficiency of rpL19)^delta CPrpL19(control-sample). Based
on this equation, enhanced POMC mRNA expression
gives ratios > 1, decreased POMC mRNA expression gives
ratios < 1. The cytokine array and western blot hyperfilms
were scanned at 400 dpi and inverted for analysis by op-
tical densitometry using Image J software 1.37v (Wayne
Rasband, National Institute of Mental Health, Bethesda,
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of loading control ± SEM after background correction.Statistical analysis
All data were analyzed with GraphPad Prism Version 4.01
for Windows (GraphPad Software, USA). Normalized
cytokine array data were analyzed using unpaired t-test
with Welch’s correction to account for the number of
experiments performed. Statistical analysis was performed
on normalized CP values (e.g. CPPOMC-CPrpL19) in case of
the qRT-PCR data; beta-endorphin immunoreactivity
values (cellular content as well as amount in the super-
natant in pg) were normalized to one million cells. Statis-
tical significance with respect to qRT-PCR data was
calculated using the non-parametric Wilcoxon signed
rank test if two groups were compared. Multiple compari-
sons of matched qRT-PCR, RIA, EIA, and Western Blot
data were performed using the non-parametric Friedman
Test; post-hoc comparisons were performed by Dunn’s
test. Behavioral data (average PPT values) were analyzed
by Two-Way repeated measures (RM) ANOVA and Bon-
ferroni correction for multiple comparisons. For all tests,
statistical significance was considered if P < 0.05.
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